Genzyme Corporation

Chris Ho

Donglai Yang

C Michael Philbrook

Harvey Lieberman

Michael Santos

Audrey Jeanjean

Pankaj Taneja

Danielle Combessis

David Rigal

The present disclosure relates to pharmaceutical compositions, including dosage forms, such as tablets or capsules, comprising venglustat, in free base, or pharmaceutically acceptable salt form, a diluent/filler and a lubricant, optionally in combination with one or more additional therapeutic agents, to processes for manufacture thereof, and to methods of use in the treatment or prevention of disease.

Pharmaceutical compositions comprising venglustat

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor ('Trk inhibitor') are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors

Pharmaceutical formulations of tropomyosin related kinase (Trk) inhibitors

Growing community of inventors

Bridgewater, NJ, United States of America

Chris Ho